GlassScriptPhysician profile
David G Prado
NPI 1073946919
$3,585.75
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $335 · 2021: $1,233 · 2022: $511 · 2023: $871 · 2024: $96.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.14 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $680.63 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $529.20 | 2019-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.03 | 2020-2023 | |
| Supernus Pharmaceuticals, INC. | $336.88 | 2021-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $253.34 | 2019-2023 | Rexulti |
| Allergan, INC. | $234.67 | 2019-2020 | |
| Abbvie INC. | $231.20 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $214.16 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $209.04 | 2020-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $108.56 | 2019-2023 | Spravato, Invega Trinza, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $88.04 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $87.88 | 2019-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $82.90 | 2022-2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $68.98 | 2022-2023 | Uzedy, Austedo Xr |
| Shire North American Group INC | $53.89 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $30.68 | 2019 | |
| Tris Pharma INC | $14.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Prado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.